In vitro and in silico evaluation of antiproliferative activity of new isoxazolidine derivatives targeting EGFR: design, synthesis, cell cycle analysis, and apoptotic …

F Alminderej, S Ghannay, MO Elsamani, F Alhawday… - Pharmaceuticals, 2023 - mdpi.com
A series of novel enantiopure isoxazolidine derivatives were synthesized and evaluated for
their anticancer activities against three human cancer cell lines such as human breast …

Metronidazole acid acyl sulfonamide: A novel class of anticancer agents and potential EGFR tyrosine kinase inhibitors

Y Luo, Y Li, KM Qiu, X Lu, J Fu, HL Zhu - Bioorganic & medicinal chemistry, 2011 - Elsevier
A series of novel metronidazole derivatives were recently reported as potent anticancer
agents targeting EGFR and HER-2 by our group [Qian, Y.; Zhang, HJ; Zhang, H.; Xu, C.; …

Synthesis and in vitro biological evaluation of novel quinazoline derivatives

Y Zhang, Y Zhang, J Liu, L Chen, L Zhao, B Li… - Bioorganic & Medicinal …, 2017 - Elsevier
A series of novel 4-arylamino-6-(5-substituted furan-2-yl) quinazoline derivatives were
designed, synthesized and evaluated on biological activities in vitro. Compound 2a, 3a and …

Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors

B Zhang, Z Liu, S Xia, Q Liu, S Gou - European Journal of Medicinal …, 2021 - Elsevier
Multi-target, especially dual-target, drug design has become a popular research field for
cancer treatment. Development of small molecule dual-target inhibitors through …

Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle

HM Patel, R Pawara, A Ansari, M Noolvi… - Bioorganic & medicinal …, 2017 - Elsevier
The epidermal growth factor receptor (EGFR) T790M mutant is found in about 50% of
clinically acquired resistance to gefitinib among patients with non-small cell lung cancer …

Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors

Y Tu, C Wang, S Xu, Z Lan, W Li, J Han, Y Zhou… - Bioorganic & medicinal …, 2017 - Elsevier
Two series of quinazoline derivatives bearing aryl semicarbazone scaffolds (9a–o and 10a–
o) were designed, synthesized and evaluated for the IC 50 values against four cancer cell …

Novel pyridine-thiazolidinone-triazole hybrid glycosides targeting EGFR and CDK-2: Design, synthesis, anticancer evaluation, and molecular docking simulation

AF Kassem, MA Omar, ES Nossier, HM Awad… - Journal of Molecular …, 2023 - Elsevier
The observed toxicity of newly designed anticancer drugs is considered as an impediment
challenging phenomenon of intense concern arising from diversity in drug targets and the …

Structure-based design, synthesis and antiproliferative action of new quinazoline-4-one/chalcone hybrids as EGFR inhibitors

M Hisham, HA Hassan, HAM Gomaa… - Journal of Molecular …, 2022 - Elsevier
A new series of quinazoline-4-one/chalcone hybrids, 7–26, was synthesized in this study as
EGFR inhibitors with antiproliferative activity. Target compounds were synthesized and in …

Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M

AA Nasser, IH Eissa, MR Oun, MA El-Zahabi… - Organic & …, 2020 - pubs.rsc.org
A new series of pyrimidine-5-carbonitrile derivatives has been designed as ATP mimicking
tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR). These compounds …

Discovery of new [1, 4] dioxino [2, 3-f] quinazoline-based inhibitors of EGFR including the T790M/L858R mutant

X Qin, Z Li, L Yang, P Liu, L Hu, C Zeng… - Bioorganic & Medicinal …, 2016 - Elsevier
Abstract A novel series of 2, 3-dihydro-[1, 4] dioxino [2, 3-f] quinazoline derivatives were
designed, synthesized and evaluated as reversible and noncovalent epidermal growth …